However, gemcitabine treatment aggravated the cancer cachexia (actual body weights, periovarian fat depositions and serum IL-6 levels) and immunosuppress (lymphatic organ weights, serum IFN-γ levels, NK cell activities, splenic TNF-α, IL-1β and IL-10 contents, histopathological atrophic changes of lymphatic organs, iNOS and TNF-α immunoreactivities in tumor masses) as compared with tumor-bearing control mice. This evidence concerns the gene IL6 and cancer.